Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Biocryst Pharma Inc (BCRX)

Biocryst Pharma Inc (BCRX)
7.30 x 1 7.53 x 1
Post-market by (Cboe BZX)
7.40 +0.18 (+2.49%) 04/17/25 [NASDAQ]
7.30 x 1 7.53 x 1
Post-market 7.38 -0.02 (-0.27%) 17:48 ET
Quote Overview for Thu, Apr 17th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
7.14
Day High
7.51
Open 7.17
Previous Close 7.22 7.22
Volume 3,353,900 3,353,900
Avg Vol 3,173,595 3,173,595
Stochastic %K 72.39% 72.39%
Weighted Alpha +42.33 +42.33
5-Day Change +0.99 (+15.44%) +0.99 (+15.44%)
52-Week Range 4.03 - 9.50 4.03 - 9.50
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,546,304
  • Shares Outstanding, K 208,960
  • Annual Sales, $ 450,710 K
  • Annual Income, $ -88,880 K
  • EBIT $ -3 M
  • EBITDA $ -13 M
  • 60-Month Beta 1.75
  • Price/Sales 3.35
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 65.07% ( +19.61%)
  • Historical Volatility 51.78%
  • IV Percentile 80%
  • IV Rank 41.42%
  • IV High 118.54% on 01/02/25
  • IV Low 27.27% on 10/11/24
  • Put/Call Vol Ratio 0.01
  • Today's Volume 347
  • Volume Avg (30-Day) 727
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 29,719
  • Open Int (30-Day) 27,399

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.07
  • Number of Estimates 5
  • High Estimate -0.04
  • Low Estimate -0.10
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +58.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.01 +23.13%
on 04/10/25
Period Open: 7.74
8.12 -8.87%
on 03/24/25
-0.34 (-4.39%)
since 03/17/25
3-Month
6.01 +23.13%
on 04/10/25
Period Open: 7.45
9.50 -22.11%
on 02/21/25
-0.05 (-0.67%)
since 01/17/25
52-Week
4.03 +83.62%
on 04/25/24
Period Open: 4.58
9.50 -22.11%
on 02/21/25
+2.82 (+61.57%)
since 04/17/24

Most Recent Stories

More News
How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry

One stock that might be an intriguing choice for investors right now is BioCryst BCRX. This is because this security in the Medical – Drugs space is seeing solid earnings estimate revision activity,...

BCRX : 7.40 (+2.49%)
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BCRX : 7.40 (+2.49%)
BioCryst to Present at Upcoming Investor Conference

BCRX : 7.40 (+2.49%)
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BCRX : 7.40 (+2.49%)
Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today

Investors clearly weren't in a forgiving mood on Monday when it came to BioCryst Pharmaceuticals (NASDAQ: BCRX) stock. After the commercial-stage biotech published its fourth-quarter and full-year 2024...

$SPX : 5,282.70 (unch)
BCRX : 7.40 (+2.49%)
BioCryst Pharmaceuticals (BCRX) Q4 2024 Earnings Call Transcript

BCRX earnings call for the period ending December 31, 2024.

BCRX : 7.40 (+2.49%)
BioCryst: Q4 Earnings Snapshot

BioCryst: Q4 Earnings Snapshot

BCRX : 7.40 (+2.49%)
BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

BCRX : 7.40 (+2.49%)
BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years

BCRX : 7.40 (+2.49%)
BioCryst to Present at Upcoming Investor Conferences

BCRX : 7.40 (+2.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential...

See More

Key Turning Points

3rd Resistance Point 7.93
2nd Resistance Point 7.72
1st Resistance Point 7.56
Last Price 7.40
1st Support Level 7.19
2nd Support Level 6.98
3rd Support Level 6.82

See More

52-Week High 9.50
Fibonacci 61.8% 7.41
Last Price 7.40
Fibonacci 50% 6.77
Fibonacci 38.2% 6.12
52-Week Low 4.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro